The Joint Corp.
8.14-0.16 (-1.93%)
Oct 29, 4:00:01 PM EDT · NasdaqCM · JYNT · USD
Key Stats
Market Cap
123.63MP/E (TTM)
-Basic EPS (TTM)
-0.06Dividend Yield
0%Recent Filings
8-K
Clinic refranchising approved
The Joint Corp. secured lender consent on September 30, 2025, to refranchise all company-owned clinics by December 31, 2025, while extending its revolving credit maturity to August 31, 2027. This one-time waiver sidesteps covenant breaches, requiring sales at fair value with at least 75% cash and zero outstanding loans during transactions. Refranchising sharpens focus on franchising, yet demands swift execution amid negative earnings realities.
8-K
CFO separation agreement finalized
The Joint Corp. finalized a separation agreement on August 22, 2025, with former CFO Jake Singleton, whose role ended June 9, 2025. The deal provides $171,958.50 in severance, $36,193.99 for accumulated time off, $15,000 additional cash, and up to six months of COBRA coverage, in exchange for a full release of claims. Equity awards follow existing terms without acceleration. This resolves the exit cleanly, minimizing disputes.
10-Q
Q2 FY2025 results
The Joint Corp. posted solid Q2 FY2025 results from continuing operations, with total revenues climbing 5.2% y/y to $13.3M on stronger royalty fees and franchise growth, while narrowing its operating loss by 36% y/y to $1.1M amid tighter cost controls. Gross margins held steady at 79.1%, up slightly from 77.7% y/y, as franchise and IT costs dipped 1.4% y/y. Diluted EPS from continuing operations improved to -$0.06 from -$0.11 y/y, reconciling neatly with 15.4M weighted shares. Cash swelled to $29.8M at quarter-end, bolstered by $7.8M from clinic sales under its refranchising push, which closed 37 locations including a $8.3M Arizona/New Mexico cluster deal recognizing no goodwill but freeing up resources. Free cash flow wasn't disclosed in the 10-Q. Yet competition from established chiropractic rivals lingers as a key risk.
8-K
Q2 revenue up 5%, refranchising advances
The Joint Corp. reported Q2 2025 revenue of $13.3 million, up 5% from last year, while refranchising 37 clinics for $11.2 million boosted franchises to 92% of its 967-clinic portfolio. System-wide sales rose 2.6% to $129.6 million, with comparable sales up 1.4%, driving consolidated Adjusted EBITDA 52% higher to $3.2 million. Yet softer trends prompted revised 2025 guidance: system-wide sales $530-550 million, low-single-digit comps, and 30-35 new franchised openings. Refranchising accelerates the pure-play franchisor shift.
8-K
Financial restatement announced
The Joint Corp. disclosed on July 24, 2025, that its 2024 audited financials and Q1 2025 interim statements require restatement due to errors in impairment calculations for clinics held for sale in discontinued operations, stemming from misapplied GAAP valuation methods. The fixes will shrink 2024's net loss by $2.2 million and boost Q1 2025 net income by $0.5 million, while lifting asset carrying values by $2.7 million cumulatively—no changes to Adjusted EBITDA or cash hit. Errors expose a material weakness in internal controls. Restatements loom soon.
IPO
Website
Employees
Sector
Industry
BTMD
Biote Corp.
2.67-0.07
CDIX
CARDIFF LEXINGTON CORPORATION
1.01+0.00
DYNT
Dynatronics Corp.
0.05+0.00
FCHS
First Choice Healthcare Solutio
0.01+0.00
HLYK
HealthLynked Corp.
1.63+0.00
HNGE
Hinge Health, Inc.
49.60-1.37
JRSS
JRSIS Health Care Corp
0.01+0.00
PAIYY
Aesthetic Medical International
0.13-0.08
PIII
P3 Health Partners Inc.
8.66-0.22
YJGJ
Yijia Group Corp.
1.61+0.00